TrialLeukemia2019

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.

Roch Houot et al.PubMed ↗Publisher ↗

No numbers read from the abstract.